TNFSF10 and chronic kidney disease: These results further support the involvement of TRAIL on cardiovascular disease since they are in agreement with previous studies demonstrating that the levels of TRAIL are reduced in patients with acute coronary syndromes [6, 36], congestive heart failure [37] and in a CKD population with an elevated risk of mortality [7].